

INFORMATION DISCLOSURE STATEMENT

Applicant : Takruri
App. No : 10/698,320
Filed : October 31, 2003
For : PIRENZEPINE OPHTHALMIC GEL
Examiner : Fay, Zohreh A.
Art Unit : 1618

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing ^{twelve}~~eleven~~ references to be considered by the Examiner. Also enclosed are twelve references as listed on the Information Disclosure Statement. The significance of the Russian-language reference SU 1827797 A3 is that it was cited in a search report of related Russian application RU 2003136735.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10/17/05

By: 
Nancy W. Versko
Registration No. 36,298
Attorney of Record
Customer No. 20,995
(805) 547-5580

IDS 1964166:vb 093005

10/20/2005 OKFLECH1 00000028 10698320

01 FC:1806

180.00 00

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/698,320
	Filing Date	October 31, 2003
	First Named Inventor	Takruri
	Art Unit	1618
(Multiple sheets used when necessary)	Examiner	Fay, Zohreh A.
SHEET 1 OF 1	Attorney Docket No.	VFORGE.006C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	1	WO 02/096418	12-05-2002	Valley Forge Pharmaceuticals		
	2	SU 1827797 A3	05-25-1996	The Temporary Interindustrial Scientific-Technological Community "Bioeffect"		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	3	BARTLETT et al., 2003, "A Tolerability Study of Pirenzepine Ophthalmic Gel in Myopic Children," J Ocul Pharmacol Ther 19: 271.	
	4	COTTRIAL et al., 1996, "The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew," Invest Ophthalmol Vis Sci 37: 1368.	
	5	KARAGEOZIAN et al., 2001, "Pirenzepine (PIR) Ophthalmic Gel: Concentration- and time-response in rabbits," Invest Ophthalmol Vis Sci 42: S59 (Abstr Nr 330).	
	6	LEECH et al., 1995, "Pirenzepine prevents form deprivation myopia in a dose dependent manner," Ophthalmic Physiol Opt 15: 351.	
	7	SHEDDEN et al., 1998, "Tolerability of Pirenzepine Ophthalmic Solution in Adult Male Volunteers," Invest Ophthalmol Vis Sci 39: S279.	
	8	SIATKOWSKI et al., 2004, "Safety and Efficacy of 2% Pirenzepine Ophthalmic Gel in Children With Myopia," Arch Ophthalmol 122: 1667.	
	9	STONE et al., 1991, "Muscarinic Antagonist Effects on Experimental Chick Myopia," Exp Eye Res 52: 755.	
	10	TAN et al., 2005, "One-Year Multicenter, Double-Masked, Placebo-Controlled, Parallel Safety and Efficacy Study of 2% Pirenzepine Ophthalmic Gel in Children with Myopia," Ophthalmology 112: 84.	
	11	TIGGES et al., 1999, "Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys," Optom Vis Sci 76: 397.	
	12	International Preliminary Examination Report from International Application No. PCT/US02/13823, Filed 1 May 2002.	

1964131:vb 093005

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.